<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/360n" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/360n/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/360n/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_360n"><akn:num>360n</akn:num><akn:heading>Priority review to encourage treatments for tropical diseases</akn:heading><akn:content><akn:p>§ 360n. Priority review to encourage treatments for tropical diseases(a) DefinitionsIn this section:(1) Priority reviewThe term “priority review”, with respect to a human drug application as defined in section 379g(1) of this title, means review and action by the Secretary on such application not later than 6 months after receipt by the Secretary of such application, as described in the Manual of Policies and Procedures of the Food and Drug Administration and goals identified in the letters described in section 101(c) of the Food and Drug Administration Amendments Act of 2007.


(2) Priority review voucherThe term “priority review voucher” means a voucher issued by the Secretary to the sponsor of a tropical disease product application that entitles the holder of such voucher to priority review of a single human drug application submitted under section 355(b)(1) of this title or section 262 of title 42 after the date of approval of the tropical disease product application.


(3) Tropical diseaseThe term “tropical disease” means any of the following:(A) Tuberculosis.

(B) Malaria.

(C) Blinding trachoma.

(D) Buruli Ulcer.

(E) Cholera.

(F) Dengue/dengue haemorrhagic fever.

(G) Dracunculiasis (guinea-worm disease).

(H) Fascioliasis.

(I) Human African trypanosomiasis.

(J) Leishmaniasis.

(K) Leprosy.

(L) Lymphatic filariasis.

(M) Onchocerciasis.

(N) Schistosomiasis.

(O) Soil transmitted helmithiasis.

(P) Yaws.

(Q) Filovirus Diseases.

(R) Zika Virus Disease.

(S) Any other infectious disease for which there is no significant market in developed nations and that disproportionately affects poor and marginalized populations, designated by order of the Secretary.


(4) Tropical disease product applicationThe term “tropical disease product application” means an application that—(A) is a human drug application as defined in section 379g(1) of this title—(i) for prevention or treatment of a tropical disease;

(ii) the Secretary deems eligible for priority review;

</akn:p></akn:content><akn:subsection eId="subsec_360n_a"><akn:num>(a)</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>(a) Definitions In this section:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360n_b"><akn:num>(b)</akn:num><akn:heading>Priority review voucher</akn:heading><akn:content><akn:p>(b) Priority review voucher</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_360n_c"><akn:num>(c)</akn:num><akn:heading>Priority review user fee</akn:heading><akn:content><akn:p>(c) Priority review user fee</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>